Cancer gene therapy and immunotherapy (Review)

International Journal of Oncology

Volumn 9, Issue 5, 1996, Pages 941-954

  Boulikas, Teni ^a  

^a Inst of Molecular Medical Sciences   (United States)

Author keywords

bcl 2; ex vivo; GM CSF; HSV tk; liposomes; MDR1; p53; retinoblastoma; tumor peptides; tumor vaccines

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; TUMOR VACCINE; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0029857555     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.5.941     Document Type: Review

References (128)

1. Anderson WF: Human gene therapy. Science 256: 808-813, 1992.
2. Riordan JF, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L, Drumm MI, Iannuzzi MC, Collins FS, Tsui L-C: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245: 1066-1073, 1989.
3. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D and Hoeijmakers JHJ: ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 71: 939-953, 1992.
4. Chen Y, Chen C-F, Riley DJ, Allred DC, Chen P-L, Von Hoff D, Osborne CK and Lee W-H: Aberrant subcellular localization of BRCA1 in breast cancer. Science 270: 789-791, 1995.
5. Boulikas T: Xeroderma pigmentosum and molecular cloning of DNA repair genes. Anticancer Res 16: 693-708, 1996.
6. Boulikas T: Gene therapy to human diseases: ex vivo and in vivo studies. Int J Oncol (In Press).
7. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239-4242, 1990.
8. Friedmann T, Yee J-K: Pseudotyped retroviral vectors for studies of human gene therapy. Nature Med 1: 275-277, 1995.
9. Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N and Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92: 1401-1405, 1995.
10. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM and Woo SLC: Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6: 1039-1044, 1995.
11. Kordower JH, Winn SR, Liu Y-T, Mufson EJ, Sladek Jr JR, Hammang JP, Baetge EE, Emerich DF: The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 91: 10898-10902, 1994.
12. Pochon NA-M, Heyd B, Déglon N, Joseph J-M, Zurn AD, Baetge EE, Hammang JP, Goddard M, Lysaght M, Kaplan F, Kato AC, Schluep M, Hirt L, Regli F, Porchet F and de Tribolet N: Clinical Protocol: Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer-encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 7: 851-860, 1996.
13. Kotin RM, Siniscalco M, Samulski RJ, Zhu X, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M and Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215, 1990.
14. Kotin RM, Linden RM, Berns KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11: 5071-5078, 1992.
15. Gregoriadis G and Neerunjun ED: Homing of liposomes to target cells. Biochem Biophys Res Comm 65: 537-544, 1975.
16. Lasic D, Papahadjopoulos D: Liposomes revisited. Science 267: 1275-1276, 1995.
17. Gabizon A, Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949-6953, 1988.
18. Klibanov AL, Maruyama K, Torchilin VP and Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268: 235-237, 1990.
19. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C and Martin FJ: Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991.
20. Senior J, Delgado C, Fisher D, Tilcock C and Gregoriadis G: Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062: 77-82, 1991.
21. Huang SK, Stauffer PR, Hong K, Guo JWH, Phillips TL, Huang A and Papahadjopoulos D: Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54: 2186-2191, 1994.
22. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND and Khaw BA: Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 6: 2716-2719, 1992.
23. Huang SK, Lee K-D, Hong K, Friend DS and Papahadjopoulos D: Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143, 1992.
24. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D and Friend DS: Extravasastion and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. Am J Pathol 143: 10-14, 1993.
25. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
26. Lasic D and Martin F (Eds): 'Stealth liposomes' CRC Press, Boca Raton, Florida, pp1-289, 1995.
27. Lee RJ, Low PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233: 134-144, 1995.
28. Ahmad I, Longenecker M, Samuel J and Allen TM: Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 53: 1484-1488, 1993.
29. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, and Benz CC: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92: 1327-1331, 1995.
30. Nabel EG, Plautz G and Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into arterial wall. Science 249: 1285-1288, 1990.
31. Lasic DD, Templeton NS: Liposomes in gene therapy. Adv Drug Del Rev (In Press).
32. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
33. Behr J-P, Demeneix B, Loeffler J-P and Perez-Mutul J: Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 86: 6982-6986, 1989.
34. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovitch P, Gallo RC and Mahan LC: Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 92: 9742-9746, 1995.
35. Schwartz B, Benoist C, Abdallah B, Scherman D, Behr J-P, and Demeneix BA: Lipospermine-based gene transfer into the newborn mouse brain is optimized by a low lipospermine/DNA charge ratio. Hum Gene Ther 6: 1515-1524, 1995.
36. Blumenthal R, Seth P, Willingham MC, Pastan I: pH-dependent lysis of liposomes by adenovirus. Biochemistry 25: 2231-2237, 1986.
37. Seth P: Adenovirus-dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein. J Virol 68: 1204-1206, 1994.
38. Curiel DT, Agarwal S, Wagner E and Cotten M: Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc Natl Acad Sci USA 88: 8850-8854, 1991.
39. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT and Birnstiel ML: High efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89: 6094-6098, 1992.
40. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT and Birnstiel ML: Coupling of adenovirus to tranferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89: 6099-6103, 1992.
41. Wagner E, Plank C, Zatloukal K, Cotten M and Birnstiel ML: Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA 89: 7934-7938, 1992.
42. Murata M, Takahashi S, Kagiwada S, Suzuki A, Ohnishi S-I: pH-dependent membrane fusion and vesiculation of phospholipid large unilamellar vesicles induced by amphiphilic anionic and cationic peptides. Biochemistry 31: 1986-1992, 1992.
43. Bullough PA, Hughson FM, Skehel JJ, Wiley DC: Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371: 37-43, 1994.
44. Midoux P, Mendes C, Legrand A, Raimond J, Mayer R, Monsigny M, Roche AC: Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res 21: 871-878, 1993.
45. Kamata H, Yagisawa H, Takahashi S, Hirata H: Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. Nucleic Acids Res 22: 536-537, 1994.
46. Bongartz J-P, Aubertin A-M, Milhaud PG and Lebleu B: Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22: 4681-4688, 1994.
47. Venkatesh LK, Arens MQ, Subramanian T, Chinnadurai G: Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA 87: 8746-8750, 1990.
48. Brady HJM, Miles CG, Pennington DJ, Dzierzak EA: Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA 91: 365-369, 1994.
49. Dimaio JM, Clary BM, Via DF, Coveney E, Papas TN and Lyerly HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205-213, 1994.
50. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261, 1994.
51. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso C-L, Dekernion JB and Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 6: 1417-1426, 1995.
52. Richards CA, Austin EA and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995.
53. Dai Y, Roman M, Naviaux RK and Verma IM: Gene therapy via primary myoblasts: Long term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 89: 10892-10895, 1992.
54. Gavaghan H: A shot in the arm for gene therapy company. Nature Med 1: 392, 1995.
55. Wilson JM, Grossman M, Raper SE, Baker JR, Newton RS, and Thoene JG: Clinical protocol. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 3: 179-222, 1992.
56. Enomaa N, Danos O, Peltonen L and Jalanko A: Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Hum Gene Ther 6: 723-731, 1995.
57. Kordower JH, Winn SR, Liu Y-T, Mufson EJ, Sladek Jr JR, Hammang JP, Baetge EE, Emerich DF: The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 91: 10898-10902, 1994.
58. Delort JP and Capecchi MR: TAXI/UAS: a molecular switch to control expression of genes in vivo. Human Gene Ther 7: 809-820, 1996.
59. Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, Bordignon C: An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251: 1363-1366, 1991.
60. Tepper RI, Pattengale PK, Leder P: Murine Interleukin-4 displays potent anti-tumor activity in vitro. Cell 57: 503-512, 1989.
61. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
62. Rosenberg SA: The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180-199, 1992.
63. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE: Use of tumor infiltrating lymphocytes and interleukin-2 in ihe immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680, 1988.
64. Aebersold P, Kasid A, Rosenberg S: Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: A case study. Hum Gene Ther 1: 373-384, 1990.
65. Rosenberg SA, Anderson WF, Blaese MR, Ettinghausen SE, Hwu P, Karp SE, Kasid A, Mule JJ, Parkinson DR, Salo JC, Schwartzentruber DJ, Topalian SI, Weber JS, Yannelli JR, Yang JC and Linehan WM: Initial proposal of clinical research project. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 3: 75-90, 1992.
66. Cassileth PA, Podack E, Sridhar K, Savaraj N and Hanlon J: Phase I study of transfected cancer cells expressing the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther 6: 369-383, 1995.
67. Pulaski BA, Yen K-Y, Shastri N, Maltby KM, Penney DP, Lord EM, and Frelinger JG: Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex 're-presentation' of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci USA 93: 3669-3674, 1996.
68. Zhu Y, Carroll M, Papa FR, Hochstrasser M and D'Andrea AD: DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci USA 93: 3275-3279, 1996.
69. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1: 1297-1302, 1995.
70. Russell SJ: Peptide-displaying phages for targeted gene delivery. Nature Med 2: 276-277, 1996.
71. Devlin JJ, Panganiban LC, Devlin PE: Random peptide libraries: A source of specific binding protein molecules. Science 249: 404-406, 1990.
72. Cwirla SE, Peters EA, Barrett RW, Dower WJ: Peptides on phage: A vast library of peptides for identifying ligands. Proc Natl Acad Sci USA 87: 6378-6382, 1990.
73. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA, Tate EH, Akeson A, Bowlin TL, Dower WJ, Barrett RW: High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 93: 7381-7386, 1996.
74. Doorbar J, Winter G: Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 244: 361-369, 1994.
75. Barry MA, Dower WJ, Johnston SA: Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries. Nature Med 2: 299-305, 1996.
76. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC and Mule JJ: Clinical protocol. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 7: 773-792, 1996.
77. Vieweg J, Rosenthal F, Bannerji R, Heston W, Fair W, Gansbacher B and Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760-1765, 1994.
78. Boulikas T: Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Anticancer Res (In press).
79. Bacchetti S and Graham FL: Inhibition of cell proliferation by an adenovirus vector expressing the human wild-type p53 protein. Int J Oncol 3: 781-788, 1993.
80. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM, Gregory RJ: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079-1088, 1994.
81. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA and Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
82. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772-5781, 1990.
83. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
84. Roth JA: Clinical protocol. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wild-type p53 and cisplatin. Hum Gene Ther 7: 1013-1030, 1996.
85. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD and Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395-405, 1995.
86. Voeller HJ, Sugars LY, Pretlow T and Gelmann EP: p53 mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994.
87. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD and Ewing CM: Molecular biology of prostate cancer. Semin Oncol 21: 514-521, 1994.
88. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86: 926-933, 1994.
89. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, and Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633, 1994.
90. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW and Thompson TC: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
91. Yang Z-Y, Perkins ND, Ohno T, Nabel EG, Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1: 1052-1056, 1995.
92. Yang C, Cirielli C, Capogrossi MC and Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-4213, 1995.
93. da Costa LT, Jen J, He T-C, Chan TA, Kinzler KW, Vogelstein B: Converting cancer genes into killer genes. Proc Natl Acad Sci USA 93: 4192-4196, 1996.
94. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
95. Bookstein R, Shew J-Y, Chen P-L, Scully P and Lee W-H: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990.
96. Horowitz JM, Yandell DW, Park S-H, Canning S, Whyte P, Buchkovich K, Harlow E, Weinberg RA, Dryja TP: Point mutational inactivation of the retinoblastoma antioncogene. Science 243: 937-940, 1989.
97. Weissman BE, Saxon PJ, Pasquale SR, Jones GR, Geiser AG, Stanbridge EJ: Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science 236: 175-180, 1987.
98. Oshimura M, Kugoh H, Koi M, Shimizu M, Yamada H, Satoh H, Barrett JC: Transfer of a normal human chromosome 11 suppresses tumorigenicity of some but not all tumor cell lines. J Cell Biochem 42: 135-142, 1990.
99. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995.
100. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
101. WAF1/CIP1 in breast epithelial cells. Cancer Res 55: 4520-4524, 1995.
102. Field AK, Davies ME, DeWitt, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DBR, Tolman RL: 9-{[2-Hydroxy-1-(hydroxymethyl)ethoxy] methyl}guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 80: 4139-4143, 1983.
103. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
104. Borrelli E, Heyman R, Hsi M and Evans RM: Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 85: 7572-7576, 1988.
105. Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300, 1990.
106. Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039-8043, 1991.
107. Su H, Chang JC, Xu SM and Kan YW: Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of ther herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 463-470, 1996.
108. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261, 1994.
109. Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SLC and Thompson TC: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7: 515-523, 1996.
110. Kimura H, Sakamoto T, Cardillo JA, Spee C, Hinton DR, Gordon EM, Anderson WF and Ryan SJ: Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: Feasibility in prevention of proliferative vitreoretinopathy. Hum Gene Ther 7: 799-808, 1996.
111. Mullen CA, Kilstrup M, Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
112. Austin EA and Huber BH: A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993.
113. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619-4626, 1993.
114. Huber BE, Austin EA, Richards CA, Davis ST, Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994.
115. Richards CA, Austin EA and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995.
116. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nature Med 2: 567-573, 1995.
117. Huber BE, Richards CA, Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc Natl Acad Sci USA 88: 8039-8043, 1991.
118. Gottesman MM and Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163-12166, 1988.
119. Marie J-P, Zittoun R and Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592, 1991.
120. Fardel O, Escande F, Drenou B, Le Bescot J, Rault B and Fauchet R: Expression of P-glycoprotein in multidrug-resistant human leukemia K562 cells during erythroid differentiation. Int J Oncol 7: 377-381, 1995.
121. Safa AR, Glover CJ, Meyers MB, Biedler JL, Felsted RL: Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 261: 6137-6140, 1986.
122. + cells. Blood 84: 1408-1414, 1994.
123. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257: 99-103, 1992.
124. Podda S, Ward M, Himelstein A, Richardson C, De La Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 89: 9676-9680, 1992.
125. Anders F, Schartl M, Barnekow A, Anders A: Xiphophorus as an in vivo model for studies on normal and defective control of oncogenes. Adv Cancer Res 42: 191-275, 1984.
126. Spandidos DA, Wilkie NM: Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310: 469-475, 1984.
127. Vogelstein B, Kinzler K: p53 function and dysfunction. Cell 70: 523-526, 1992.
128. Han J, Sabbatini P, Perez D, Rao L, Modha D and White E: The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10: 461-477, 1996.